Efficacy of mast cell directed therapies in irritable bowel syndrome: a systematic review
ReviewHumansWith polydatin (palmitoylethanolamide-polydatin was one of the therapies reviewed)
This study tested palmitoylethanolamide together with polydatin (palmitoylethanolamide-polydatin was one of the therapies reviewed). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Review
- Subjects
- 11 trials with 943 IBS patients and 197 controls
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Abdominal pain and changes in stool frequency or consistency after mast cell directed therapies compared with placebo or control.
What the authors reported
The review found:
- From 1,384 citations, 11 trials were included: ten randomised controlled trials and one cohort study, only three at low risk of bias.
- This limited evidence suggests an overall improvement in key symptoms after disodium cromoglycate, ebastine, ketotifen or palmitoylethanolamide-polydatin compared with controls.
- The authors call for further high-quality research.
Limits of this study
A systematic review without meta-analysis; most included trials were at risk of bias. Results for PEA-polydatin are not separated out in the abstract. The authors declare no conflict of interest.
Source
PubMed 38431786 · doi:10.51821/87.1.12487
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.